



HAIR DISORDERS

## RETROSPECTIVE ANALYSIS OF THE 23 FOLICULITIS DECALVANS PATIENTS: A SINGLE CENTER EXPERIENCE

Serkan Yazici<sup>(1)</sup> - Hayriye Saricaoglu<sup>(1)</sup> - Ali Bozdag<sup>(1)</sup> - Saduman Adim Balaban<sup>(1)</sup> - Kenan Aydogan<sup>(1)</sup> - Emel Bulbul Baskan<sup>(1)</sup>

Uludag University School Of Medicine, Dermatology, Bursa, Turkey (1)

INTRODUCTION: Folliculitis decalvans (FD) is a rare, primary neutrophilic cicatricial alopecia that classically presents as an expanding patch of alopecia with peripheral pustules on the scalp.

Because of irreversible outcome of the disease, systemic therapy should be used in early inflammatory stages of the disease, without allowing their reversible scar formation and permanent hair loss. We present here the clinical and demographic features, and outcome of FD patients from TURKEY.

METHOD: We retrospectively analysed the 23 FD cases who were followed up between January 2005 to september 2018. All patients were clinically and histopathologically diagnosed as FD according to the criteria of the North American Hair Research Society. Clinical and demographic features and treatment parameters were retrieved from computerized medical records.

RESULTS: A total of 23 patients 17 were male and six were female. The age of onset ranged from 12 to 66 years with mean age of onset was: $31.91 \pm 15.25$  yrs and median age of onset was:33.0 yrs. Duration of the disease varied between four years to ten years with a mean duration of the disease was: $3.43 \pm 2.92$  yrs. Four of there maining 13 patients shoved complet remission with systemic isotretinoin therapy. Nine of the 13 patients did not respond the therapy (three were systemic isotretinoin, six were used systemic antibiotics). Treatment durations were ranged between three months to three years. There is no any serious side effects. Of the nine nonresponders six patients lesions were progressed.

CUNCLUSION: Clinic and demographic features of our cases compatible with previous literature. Although the treatment does not altered the disease course, in our experience systemic isotretinoin therapy seems to safe and effective option for the patients.





